Prostate Cancer Clinical Trial

Insulin Resistance and Androgen Deprivation Therapy

Summary

Prostate cancer is the most common malignancy amongst men in United States. Androgen deprivation therapy (ADT) with long acting gonadotropin releasing hormone agonists is routinely used as adjuvant therapy in intermediate and high risk localized or locally advanced prostate cancer. Since ADT induces insulin resistance and diabetes, it is important that cellular and molecular effects of ADT are investigated to define precisely the mechanisms involved in the pathogenesis of insulin resistance. Pioglitazone, a known insulin sensitizer, may provide amelioration of insulin resistance in these patients.

View Full Description

Full Description

Investigators plan to conduct a prospective, randomized, double-blind, placebo-controlled trial in 44 men with nonmetastatic prostate cancer who are receiving ADT with long acting GnRH agonist (study group). Study subjects will undergo insulin clamp, subcutaneous fat biopsy, muscle biopsy, have a blood sample taken and fibroscan performed prior to randomization of study drug. They will then be randomized to 30 mg pioglitazone or placebo tablet daily for 6 months. Blood samples will be drawn 2 and 4 months following the initiation of the study drug. The final study visit will be at 6 months. Subjects will undergo clamp, fat biopsy, muscle biopsy, blood sampling, fibroscan and will be discharged from the study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Prostate cancer, non-metastatic
Have been on ADT with long acting GnRH agonist continuously for last 3 months, AND planning to continue ADT for at least 6 months

Exclusion Criteria:

Used pioglitazone in last 6 months
Heart Failure NYHA Class 3 or 4
Known to have osteoporosis at this time.
history of bladder cancer
Hemoglobin <8 gdl
eGFR <15 mlmin1.73m2
liver enzymes (ALT or AST) >3 times the upper limit of normal

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

44

Study ID:

NCT04995978

Recruitment Status:

Recruiting

Sponsor:

St. Louis University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Saint Louis Univeristy
Saint Louis Missouri, 63104, United States More Info
Jennifer Newman
Contact

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

44

Study ID:

NCT04995978

Recruitment Status:

Recruiting

Sponsor:


St. Louis University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.